Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $20.29

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have earned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $20.2857.

Several equities analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Monday, April 20th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, June 23rd. Wall Street Zen downgraded shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Finally, Rodman & Renshaw began coverage on shares of Enanta Pharmaceuticals in a report on Thursday, March 26th. They issued a “buy” rating and a $20.00 target price for the company.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA opened at $13.74 on Friday. The stock has a 50 day moving average price of $13.31 and a two-hundred day moving average price of $13.53. The firm has a market capitalization of $399.56 million, a P/E ratio of -5.30 and a beta of 0.96. Enanta Pharmaceuticals has a 52 week low of $6.45 and a 52 week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.01. The company had revenue of $17.16 million for the quarter, compared to analyst estimates of $17.03 million. Enanta Pharmaceuticals had a negative return on equity of 64.04% and a negative net margin of 89.56%. On average, equities analysts forecast that Enanta Pharmaceuticals will post -1.79 earnings per share for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ENTA. Janus Henderson Group PLC boosted its stake in shares of Enanta Pharmaceuticals by 1.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock worth $47,717,000 after buying an additional 54,396 shares during the last quarter. Farallon Capital Management LLC increased its position in shares of Enanta Pharmaceuticals by 30.6% during the fourth quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock valued at $43,719,000 after acquiring an additional 650,000 shares during the last quarter. Krensavage Asset Management LLC lifted its holdings in Enanta Pharmaceuticals by 30.8% during the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after acquiring an additional 651,946 shares during the period. Millennium Management LLC lifted its holdings in Enanta Pharmaceuticals by 50.2% during the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after acquiring an additional 449,945 shares during the period. Finally, Spruce Street Capital LP boosted its position in Enanta Pharmaceuticals by 139.3% in the first quarter. Spruce Street Capital LP now owns 932,598 shares of the biotechnology company’s stock worth $11,779,000 after purchasing an additional 542,911 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.